A phase II study of gemcitabine in combination with oxaliplatin as first line chemotherapy in patients with inoperable biliary tract adenocarcinoma

被引：0
|
作者：
Kim, H. [1 ]
Lee, S. [2 ]
Bae, S. [3 ]
Kim, C. [1 ]
Lee, N. [2 ,3 ]
Lee, K.
Park, S. [1 ]
Won, J. [1 ,2 ]
Hong, D.
Park, H. [2 ]
机构：
[1] Soonchunhyang Univ Hosp, Puchon, South Korea
[2] Soonchunhyang Univ Hosp, Seoul, South Korea
[3] Soonchunhyang Univ Hosp, Cheonan, South Korea
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71062-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页码：277 / 277
页数：1
相关论文
共 50 条
  • [41] Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
    Lee, Kyung Hee
    Kim, Min Kyoung
    Kim, Yeol Hong
    Ryoo, Baek Yeol
    Lim, Ho Yeong
    Song, Hong Suk
    Kim, Hoon Kyo
    Lee, Myung Ah
    Im, Seock Ah
    Chang, Heung Moon
    Cho, Jae Yong
    Zang, Dae Young
    Kim, Bong Seog
    Kim, Jun Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 317 - 325
  • [42] Gemcitabine and oxaliplatin combination as the first-line treatment in advanced pancreatic cancer: A multicenter phase II study
    Lee, K.
    Kim, M.
    Kim, Y.
    Ryoo, B.
    Lim, H.
    Song, H.
    Kim, H.
    Lee, M.
    Im, S.
    Chang, H.
    Cho, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
    Evans, T. R. Jeffry
    Wylie, Eileen
    Garcia, Jorge Curto
    Coxon, Fareeda
    Wall, Lucy
    Eatock, Martin
    Maughan, Tim
    Highley, Martin
    Zimmerli, Priska Butzberger
    ANNALS OF ONCOLOGY, 2006, 17 : 320 - 320
  • [44] Phase II trial of S-1 in combination with oxaliplatin (SOx) in previously untreated patients with recurrent or inoperable biliary tract cancer
    Oh, S.
    Lee, G.
    Kim, H.
    Kim, T.
    Kim, H.
    Kang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Pembrolizumab in combination with first-line chemotherapy with gemcitabine-cisplatin for advanced biliary tract cancer
    d'Abrigeon, Constance
    Cindy, Neuzillet
    BULLETIN DU CANCER, 2024, 111 (06) : 541 - 542
  • [46] Effectiveness study of gemcitabine, oxaliplatin, and capecitabine as first-line treatment for nonresectable biliary tract cancer
    Jensen, Lars Henrik
    Mellergaard, Anne Haahr
    Hoegdall, Dan
    Larsen, Ole
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [47] A phase II trial of gemcitabine plus cisplatin (GP) in patients with inoperable biliary tract cancer (BTC).
    Park, JO
    Kang, WK
    Kim, TY
    Lee, MA
    Ahn, MJ
    Kim, HK
    Lee, NS
    Lim, HY
    Park, BJ
    Kim, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 341S - 341S
  • [48] A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer
    Kanai, Masashi
    Yoshimura, Kenichi
    Tsumura, Takehiko
    Asada, Masanori
    Suzuki, Chihiro
    Niimi, Miyuki
    Matsumoto, Shigemi
    Nishimura, Takafumi
    Nitta, Takashi
    Yasuchika, Kentaro
    Taura, Kojiro
    Mori, Yukiko
    Hamada, Akihiko
    Inoue, Naoya
    Tada, Shinsuke
    Yanagihara, Kazuhiro
    Yazumi, Shujiro
    Osaki, Yukio
    Chiba, Tsutomu
    Ikai, Iwao
    Fukushima, Masanori
    Uemoto, Shinji
    Hatano, Etsuro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1429 - 1434
  • [49] A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer
    Masashi Kanai
    Kenichi Yoshimura
    Takehiko Tsumura
    Masanori Asada
    Chihiro Suzuki
    Miyuki Niimi
    Shigemi Matsumoto
    Takafumi Nishimura
    Takashi Nitta
    Kentaro Yasuchika
    Kojiro Taura
    Yukiko Mori
    Akihiko Hamada
    Naoya Inoue
    Shinsuke Tada
    Kazuhiro Yanagihara
    Shujiro Yazumi
    Yukio Osaki
    Tsutomu Chiba
    Iwao Ikai
    Masanori Fukushima
    Shinji Uemoto
    Etsuro Hatano
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1429 - 1434
  • [50] Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer
    Mark K. Doherty
    Vincent C. Tam
    Mairéad G. McNamara
    Raymond Jang
    David Hedley
    Eric Chen
    Neesha Dhani
    Patricia Tang
    Hao-Wen Sim
    Grainne M. O’Kane
    Stephanie DeLuca
    Lisa Wang
    Theresa Pedutem
    Jennifer J. Knox
    British Journal of Cancer, 2022, 127 : 1473 - 1478
12345